LYL314 + Fludarabine + Cyclophosphamide
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Non-Hodgkin Lymphoma
Conditions
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Trial Timeline
May 9, 2023 → Jun 30, 2031
NCT ID
NCT05826535About LYL314 + Fludarabine + Cyclophosphamide
LYL314 + Fludarabine + Cyclophosphamide is a phase 1/2 stage product being developed by Lyell Immunopharma for Relapsed Non-Hodgkin Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05826535. Target conditions include Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Non-Hodgkin Lymphoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05826535 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Relapsed Non-Hodgkin Lymphoma